Centogene announces CFO transition and appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

February 2022

Centogene announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the company effective March 31, 2022, after the expected filing date of Centogene’s Annual Report on Form 20-F. Miguel Coego Rios will join the company on February 08, 2022, and work closely through the transition with current Chief Financial Officer René Just. The company has initiated a search for a permanent Chief Financial Officer; both internal and external candidates will be evaluated.

Kim Stratton, Centogene’s Chief Executive Officer said: “It is a privilege to welcome Miguel Coego Rios to the Centogene team. With more than a decade of experience in senior finance roles in the biopharma sector, the expertise that Miguel brings is invaluable. I have worked with him in previous roles, and we are looking forward to the contributions he will bring to Centogene as we position ourselves as the unique and essential partner in rare, metabolic and neurodegenerative diseases.”

Miguel Coego Rios said: “The work that Centogene is doing from diagnostics, to discovery, to clinical development, to market access & expansion, in rare, metabolic, and neurodegenerative diseases offers real hope to patients around the world,” “The company has recently attracted a very solid financial foundation to accelerate growth and innovation. Centogene can now focus on the next step in the evolution of its strategy, and I look forward to enhancing the value of Centogene by ensuring optimal resource allocation on our strategic path forward and to thereby contribute to maximizing stakeholder value. I am excited to be joining a highly motivated team with the goal to deliver results and inflection milestones.”

Miguel Coego Rios is an experienced senior executive with broad expertise in finance and commercial leadership roles in the pharmaceutical and biotech sectors. He has an extensive track record in achieving sales and expenses targets, team management and development, and steering multi-country projects. Most recently, he was Vice President & General Manager South Europe at Orphazyme A/S, a late-stage clinical biotech. Before that he was Vice President & CFO EMEA at Mundipharma, a multinational pharmaceutical company. Earlier in his career, he served in several senior management positions at Shire Pharmaceuticals between 2011 and 2019, most recently as CFO LATAM and General Manager of the Andean region. Miguel Coego Rios has gained notable international exposure having completed positions in Colombia, Brazil, Spain, and the UK.

The link to the article can be found here.